Floridienne S.A. Overview
Floridienne is a family-anchored Belgian industrial holding that builds and controls leaders in niche markets. Since 2023 it has become, economically, a listed proxy for BioFirst Group, which it controls at 59.1%. BioFirst describes itself as the world's largest pure-play agricultural biologicals group. It combines Biobest (beneficial insects, bumblebee pollination and greenhouse integrated pest management) with BIOTROP (Brazil's leading microbial inoculants, biostimulants and biopesticides for open-field row crops), BioWorks (US biopesticides) and Plant Products (North American distribution).
Life Sciences generated 74% of FY2025 group turnover of €725.9m and 87% of divisional EBITDA. The Life Sciences division also includes Natix, a natural-extracts platform for enzymes, essential oils and snail extracts. Two smaller pillars complete the portfolio. Gourmet Food (€155m) makes cold sauces and gastronomic specialities for Benelux and French retail. The Chemicals/Recycling division (€32m) comprises SNAM, which recycles EV and industrial batteries in France, and Kimflor, a Turkish maker of PVC stabilisers. The investment case rests on structural substitution of synthetic agrochemicals by biologicals, set against FX exposure (USD, CAD, BRL), heavy minority interests and thin conversion of EBITDA into group-share net profit.
Company's own description
In every regulated release, Floridienne presents itself as a Belgian industrial group listed on Euronext Brussels that ranks among European or world leaders in market niches. It says its activities are concentrated in three sectors: Life Sciences, Gourmet Food and Chemicals. The FY2025 release and the H1 2026 report increasingly call the third pillar the Recycling Division (source: FY2025 results, 31 Mar 2026; H1 2026 report, 30 Sep 2026).
Independent characterisation
| Business | Value-chain position | Revenue model | Customers | End-markets |
|---|---|---|---|---|
| Biobest (BioFirst) | Producer (insect rearing, bumblebee hives) plus distributor/advisor | Product sales, with technical-advisory service embedded | Greenhouse growers (vegetables, soft fruit, ornamentals), distributors | Protected horticulture: Europe, North America, Mexico, Turkey, Australia, etc. |
| BIOTROP (BioFirst) | Biotech developer and manufacturer (fermentation of beneficial bacteria and fungi) | Product sales, multi-channel (distributors, co-ops, direct) | Row-crop farmers (soy, corn, cotton, sugarcane) | Brazilian open-field agriculture; rollout to the US and Europe |
| BioWorks (BioFirst) | Biopesticide developer and manufacturer | Product sales | Greenhouse, ornamental and specialty-crop growers | United States |
| Plant Products (BioFirst) | Distributor of integrated pest management and horticultural inputs | Distribution margin | Greenhouse growers | Canada and US |
| Natix | Extractor and producer of natural bioactives (enzymes incl. bromelain and pancreatin, essential oils, snail slime) | B2B ingredient sales | Nutrition, pharma, nutraceutical and cosmetics manufacturers | Global |
| Food Division | Food manufacturer (private label and brands) | Product sales; highly seasonal (year-end festivities) | Mass retail (Belgium, France), food service, export | Packaged food |
| SNAM | Recycler of batteries (Li-ion, NiMH, NiCd) recovering purified metals | Gate fees plus sale of recovered metals (commodity-linked) | Collection schemes, OEMs, industry | European battery end-of-life |
| Kimflor | Chemical manufacturer (Ca-Zn and heavy-metal-free PVC stabilisers) | Product sales | PVC pipe and fitting makers | Turkish and regional construction |
Floridienne is a controlled holding company with operating consolidation. It fully consolidates subsidiaries in which it often holds less than 100%, so a large and growing slice of consolidated profit belongs to minorities.
Minority equity is large: At 30 Jun 2026, non-controlling interests were €278.4m against Floridienne shareholders' equity of €399.3m.
Group-share profit is thin: FY2025 consolidated net profit was €15.1m, of which the group share was €7.9m.
The group's value chain positions are as follows.
The revenue mix is overwhelmingly product sales. There is no subscription or licensing revenue of note; some advisory services are bundled in Biobest's offering. An exact product/service split is NPD.
Strategy
Stated strategy themes (FY2025 results and H1 2026 report)
-
Niche leadership. Hold majority positions in high-potential niche markets; the Terhormon step-up is cited explicitly as an example.
-
Biologicals as the core growth engine. Build BioFirst into a global, full-range biologicals platform covering biocontrol, inoculants, biostimulants and pollination, across protected and open-field crops.
-
Internationalising BIOTROP. Roll out BIOTROP's inoculants, biofertilisers and biopesticides beyond Brazil into North America and Europe. Management expects EU regulatory initiatives to speed up approval of biocontrol products and so support medium-term growth.
-
Capacity-led organic growth. Capacity investment at BioFirst (Belgium, Brazil), Food (cold sauces from 2026) and SNAM (battery recycling volumes).
-
Operational efficiency in Food. Withdraw unprofitable references, specialise gastronomic-speciality sites and enforce strict cost control.
-
Structural tailwinds in Recycling. EV fleet electrification will supply end-of-life batteries, while EU rules raise targets for collection, recycling efficiency and recycled content.
Strategic initiatives, last 24 months
| Date | Initiative | Detail |
|---|---|---|
| 2,024 | BioFirst brand architecture | Biobest becomes BioFirst Group: Biobest (macrobials, pollination) and BIOTROP (microbials) |
| 2024–2025 | Capacity programmes | New Biobest (Belgium) and BIOTROP (Brazil) capacity; SNAM capacity ramp 2025; Food cold-sauce lines |
| Oct 2024 | Recycling refocus | Sale of Vera Chimie Développements; SNAM concentrates on batteries |
| Apr 2025 | Asia-Pacific consolidation | Bugs for Bugs to 100% |
| Sep 2025 | Natix upstream integration | Terhormon majority secures pancreatin supply |
| Feb 2026 | Share split 1:10 | To improve accessibility and liquidity (rationale inferred) |
| Aug 2026 | BIOTROP North America platform | BioWorks plus BIOTROP USA under one GM; revenue target above US$260m by 2034 |
| Oct 2026 | BIOTROP to 100% | Simplifies structure and accelerates synergy capture |
Guidance and targets
FY2025 guidance: (H1 2025): results broadly in line with 2024. Actual EBITDA came in at €110.0m versus €116.8m.
FY2026 guidance: (FY2025 results): the Board expects higher results in 2026. The H1 2026 report states a positive outlook for the year as a whole.
Quantified medium-term group targets: NPD. Only the BIOTROP North America 2034 revenue target and the BioWorks US$100m target are quantified.
Products & Services
Granular SKU-level specifications, launch years and pricing are largely NPD in Floridienne's filings. The catalogue below is built from filings plus subsidiary communications.
Life Sciences — BioFirst Group
| Line / brand | Description | Target customer | Notes |
|---|---|---|---|
| Biobest — beneficial insects and mites (macrobials) | Mass-reared predatory mites, parasitic wasps and predatory bugs for biological control of whitefly, thrips, spider mite, aphids, etc. | Greenhouse vegetable, soft-fruit and ornamental growers | Core historical business. Faced weaker pest pressure and keener North American competition in 2025–H1 2026 (H1 2026 report). |
| Biobest — bumblebee pollination | Commercial bumblebee hives for tomato and soft-fruit pollination | Greenhouse and tunnel growers | Biobest Antalya (Turkey) is a leader in bumblebee pollination (FY2023 results). |
| Biobest — biopesticides and registrations | Microbial and botanical biopesticides; regulatory registration services via Real IPM UK | Growers; distributors | Real IPM UK handles European biopesticide registrations (FY2023 results). |
| Biobest — monitoring and digital | Pest monitoring; minority bets in Ecoation (AI crop monitoring) and Arugga (robotic pollination) | Large greenhouse operators | Financial stakes €6.7m and €2.3m (H1 2025 report). |
| BIOTROP — inoculants | Bacterial inoculants (e.g., nitrogen-fixing) for soybean and other row crops | Brazilian row-crop farmers, co-ops, distributors | Portfolio built on proprietary formulations and patents (FY2025 results). |
| BIOTROP — biostimulants and biofertilisers | Microbial biostimulants and biofertilisers for crop and soil health | Row-crop and specialty farmers | Rolling out in North America and Europe (FY2025 results). |
| BIOTROP — biopesticides | Bacterial and fungal biocontrol agents for open-field pests and diseases | Row-crop farmers | 2026 capacity investment targets 23 million litres of beneficial bacteria and 600 t of beneficial fungi (Revista Cultivar, Oct 2026). |
| BIOTROP USA | Broad-acre biologicals for soybeans, corn, wheat, cotton and peanuts | US Corn Belt growers | Part of the BIOTROP North America platform since Aug 2026 |
| BioWorks | US biopesticides for greenhouse, ornamentals and specialty crops | US horticulture | Target of US$100m revenue by 2034; combined BIOTROP North America target above US$260m by 2034 (HortiDaily, Aug 2026) |
| Plant Products | Distribution of integrated pest management and grower inputs in Canada and the US | Greenhouse growers | Over €100m turnover in 2022 (FY2022 results) |
| Bugs for Bugs | Australian producer and distributor of beneficial organisms | Australian growers | 100% owned since Apr 2025 |
| Beneficial Insectary / Sierra Biologicals / Agrotech | North American insectary; US integrated pest management distribution; Austrian distribution | Growers, distributors | Acquired 2021–2023 |
Life Sciences — Natix (natural extracts)
| Line | Description | End-market |
|---|---|---|
| Plant enzymes (e.g., bromelain via JV PT Bromélaine, Indonesia) | Proteolytic enzymes | Nutrition, pharma, food processing |
| Animal-origin enzymes (pancreatin via Terhormon, Italy) | Pancreatic enzymes | Pharma and nutraceutical |
| Essential oils | Natural aromatic extracts | Flavours, fragrances, cosmetics |
| Snail slime extracts | Cosmetic bioactive | Cosmetics / skincare |
Food Division
| Line | Description | Notes |
|---|---|---|
| Cold sauces | Mayonnaise-type and emulsified cold sauces for retail, private label and export | Growth engine; additional capacity commissioned from 2026; land reserve acquired for expansion (H1 2025 report) |
| Gastronomic specialities | Snail-based dishes, seafood (e.g., scallops), festive products | Hurt by weak French consumption in 2025; site-specialisation plan under way (FY2025 results; H1 2026 report) |
| Mediterranean range / spreads and salads | Dips, spreads, fish salads | Production and distribution reorganised in 2023 (FY2023 results) |
Chemicals / Recycling Division
| Line | Description | Notes |
|---|---|---|
| SNAM — battery recycling | Collection and hydrometallurgical/pyrometallurgical recycling of Li-ion, NiMH and NiCd batteries; resale of purified metals (Ni, Co, Cd, etc.) | New capacities commissioned 2025; volumes rising in H1 2026 (H1 2026 report). A battery reconditioning activity was halted in 2023 (€1.2m impairment). |
| Kimflor — PVC stabilisers | Calcium-zinc and heavy-metal-free stabilisers for PVC pipes and fittings | Turkish market; IAS 29 hyperinflation accounting applies |
Financial Narrative
Sources: Floridienne Key Figures 2023 (FY2019–FY2023); FY2023, FY2024 and FY2025 results releases. FY2021 revenue of €353.1m is as restated in the 2023 five-year table.
Income statement
Commentary. FY2022 was a step-change year: the Plant Products acquisition lifted revenue by 47% and EBITDA hit a then-record €60.4m. FY2023 was a "transition" year:
-
Biobest had a weak season (extreme weather, European growers idling heated greenhouses on energy costs, weak USD/CAD).
-
€5.9m of non-recurring BIOTROP deal costs were booked.
-
A €2.8m hyperinflation charge hit Kimflor and a €1.2m impairment hit SNAM (FY2023 results).
FY2024 was the inflection, as the first full year of BIOTROP consolidation more than doubled EBITDA to €116.8m. FY2025 showed the vulnerability of a business priced in euros but earning in USD, CAD and BRL:
-
Revenue still grew 4.1%.
-
EBITDA fell €6.8m.
-
Group-share profit halved, hit by €4.2m of Turkish hyperinflation charges, unrealised FX losses and €9.4m of purchase-price-allocation amortisation (FY2025 results).
Balance sheet
The 2025 asset split comes from the H1 2026 comparative.
Additional balance sheet detail
Goodwill plus intangibles of roughly €585m represented about 48% of total assets at end-2024 and are almost entirely BioFirst-related: €386m of goodwill sits in Life Sciences (H1 2025 segment note). Trade working capital (inventories plus receivables minus payables) was about €172m at end-2024, or 24.7% of revenue (derived).
Cash flow
FY2024 and FY2025 operating cash flow, capex and free cash flow were not captured in the releases reviewed (NPD here; see the FY2025 annual financial report of 30 Apr 2026).
Shareholder returns
Dividend paid to Floridienne shareholders: €2.94m in June 2025 for FY2024 (€3.00 gross × shares excluding treasury) (H1 2025 report, note 20).
Buybacks: none in H1 2025; small buyback transactions in Oct–Dec 2025 (treasury rose by 738 pre-split shares). No large authorisation amount was disclosed in the sources reviewed (NPD).
Ratios (derived unless stated)
Ratio notes
- ROE for FY2021–FY2023 and payout for FY2021–FY2023 are company-reported; the rest are derived.
Current ratio: 2.04x at end-2024, 1.84x at Jun 2025 and 1.79x at end-2025. It fell to 1.30x at Jun 2026: current liabilities rose from €212.2m to €295.5m as non-current liabilities fell from €413.7m to €325.3m. This is consistent with debt maturities and the BIOTROP minority put moving into current (H1 2026 report; interpretation is the analyst's).
Interest cover (EBITDA / debt burden): about 2.8x in both H1 2025 and H1 2026. EBIT / debt burden was about 1.1x in H1 2026, which is thin.
ROIC: not computed reliably because annual EBIT and tax are not available (NPD).
Cash conversion cycle: NPD (COGS not available on a comparable basis). End-2024 inventory of €96.9m against H1 2025 annualised raw-material costs of about €322m implies roughly 110 days of inventory (rough, derived).
Interpretation. The 2023 equity raises at the BioFirst level transformed the balance sheet. Solvency jumped to 54%, but minorities became about 40% of total equity. Since then, leverage has crept back up:
-
Net debt rose from €203m (FY2023) to €303m (Jun 2026), driven by BioFirst capacity capex.
-
Net debt to FY2025 EBITDA is about 2.4x, and roughly 2.7x on Jun 2026 net debt (derived, using trailing EBITDA of about €114.5m = FY2025 €110.0m − H1 2025 €36.0m + H1 2026 €40.5m).
Profitability at group-share level is structurally low. Even record FY2024 produced only a 3.9% ROE, because:
-
Minorities take about half of consolidated profit.
-
Acquisition-related amortisation runs at €9–10m a year.
-
FX and hyperinflation charges recur.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Principal entities / brands |
|---|---|---|
Life Sciences | Biological crop protection (macrobials and microbials), pollination, biostimulants, inoculants; natural extracts | BioFirst Group (Biobest, BIOTROP, BioWorks, Plant Products, Beneficial Insectary, Bugs for Bugs, Biobest Antalya, Real IPM, Sierra Biologicals, Agrotech); Natix (incl. Terhormon; JV PT Bromélaine, Indonesia) |
Food ("Gourmet Food") | Cold sauces, gastronomic specialities (snails, seafood, Mediterranean range), spreads, salads | French and Belgian subsidiaries; Karras is named as a subsidiary with minorities. |
Chemicals / Recycling | Battery recycling; PVC stabilisers | SNAM (France); Kimflor (Turkey) |
Corporate | Holding services to subsidiaries; food-products trading | Floridienne S.A. |
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Life Sciences revenue (EUR Mn) | 337.1 | 359.4 | 507.1 | 538.3 |
Food revenue (EUR Mn) | 135.9 | 146.6 | 151.0 | 155.2 |
Chemicals/Recycling revenue (EUR Mn) | 45.4 | 43.3 | 39.3 | 32.4 |
Group revenue (EUR Mn) | 518.3 | 549.3 | 697.4 | 725.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Life Sciences EBITDA (EUR Mn) | 47.8 | 41.2 | 102.3 | 95.4 |
Food EBITDA (EUR Mn) | 6.3 | 8.1 | 11.0 | 11.1 |
Chemicals/Recycling EBITDA (EUR Mn) | 8.1 | 9.0 | 5.3 | 5.7 |
Corporate EBITDA (EUR Mn) | -1.7 | -2.4 | -1.9 | -2.3 |
Group EBITDA (EUR Mn) | 60.4 | 56.0 | 116.8 | 110.0 |
Results by Segment — Life Sciences net result
| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Life Sciences net result (EUR Mn) | 13.3 | 8.1 | 27.7 | 13.3 |
Food net result (EUR Mn) | 1.3 | 2.2 | 4.1 | 5.4 |
Chemicals/Recycling net result (EUR Mn) | 6.7 | 1.7 | 2.2 | -0.3 |
Corporate net result (EUR Mn) | -2.8 | -3.4 | -3.0 | -3.4 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Life Sciences EBITDA margin (%) | 14.2 | 11.5 | 20.2 | 17.7 |
Food EBITDA margin (%) | 4.6 | 5.5 | 7.3 | 7.2 |
Chemicals EBITDA margin (%) | 17.8 | 20.8 | 13.5 | 17.6 |
Life Sciences share of revenue (%) | 65.0 | 65.4 | 72.7 | 74.2 |
Food share of revenue (%) | 26.2 | 26.7 | 21.7 | 21.4 |
Chemicals share of revenue (%) | 8.8 | 7.9 | 5.6 | 4.5 |
Life Sciences revenue growth YoY (%) | 75.8 | 6.6 | 41.1 | 6.2 |
Food revenue growth YoY (%) | 11.0 | 7.9 | 3.0 | 2.8 |
Chemicals revenue growth YoY (%) | 0.0 | -4.6 | -9.2 | -17.6 |
Results by Segment (Half-Yearly)
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Life Sciences revenue (EUR Mn) | 236.3 | 259.5 | 265.6 |
Food revenue (EUR Mn) | 61.6 | 62.8 | 65.1 |
Chemicals/Recycling revenue (EUR Mn) | 19.6 | 15.1 | 17.6 |
Life Sciences EBITDA (EUR Mn) | 35.7 | 34.0 | 34.5 |
Food EBITDA (EUR Mn) | 1.7 | 1.1 | 2.8 |
Chemicals/Recycling EBITDA (EUR Mn) | 3.2 | 2.4 | 4.6 |
Life Sciences net result (EUR Mn) | 6.8 | -4.4 | 1.0 |
Food net result (EUR Mn) | -1.2 | -0.9 | -0.1 |
Chemicals/Recycling net result (EUR Mn) | 1.1 | -0.5 | 2.3 |
Corporate net result (EUR Mn) | -1.3 | -2.4 | -1.9 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 353.1 | 518.3 | 549.3 | 697.4 | 725.9 |
EBITDA (EUR Mn) | 45.7 | 60.4 | 56.0 | 116.8 | 110.0 |
Consolidated net result (EUR Mn) | 18.6 | 18.5 | 8.6 | 30.9 | 15.1 |
Net result group share (EUR Mn) | 13.2 | 12.0 | 3.5 | 15.7 | 7.9 |
EPS basic pre-split (EUR) | 13.48 | 12.29 | 3.62 | 16.07 | 8.11 |
EPS basic split-adjusted (EUR) | 1.348 | 1.229 | 0.362 | 1.607 | 0.811 |
Gross DPS pre-split (EUR) | 2.50 | 2.50 | 2.50 | 3.00 | 3.00 |
Gross DPS split-adjusted (EUR) | 0.25 | 0.25 | 0.25 | 0.30 | 0.30 |
EBITDA margin (%) | 12.9 | 11.7 | 10.2 | 16.7 | 15.2 |
Consolidated net margin (%) | 5.3 | 3.6 | 1.6 | 4.4 | 2.1 |
Group-share net margin (%) | 3.7 | 2.3 | 0.6 | 2.3 | 1.1 |
Income Statement
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue (EUR Mn) | 317.5 | 337.4 | 348.3 |
EBITDA (EUR Mn) | 39.6 | 36.0 | 40.5 |
EBIT (EUR Mn) | 19.6 | 13.4 | 15.5 |
Debt burden (EUR Mn) | -11.8 | -12.7 | -14.3 |
Other financial result (EUR Mn) | -0.3 | -9.8 | -1.4 |
Pre-tax result (EUR Mn) | 8.2 | -9.1 | 0.4 |
Consolidated net result (EUR Mn) | 5.3 | -8.2 | 1.3 |
Group-share net result (EUR Mn) | 1.3 | -6.4 | -0.7 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | 417.4 | 608.1 | 1,262.3 | 1,221.8 | 1,244.7 |
Non-current assets (EUR Mn) | 221.3 | 356.6 | 863.2 | 831.6 | 865.5 |
Current assets (EUR Mn) | 196.0 | 251.6 | 399.1 | 390.1 | 379.2 |
Floridienne shareholders' equity (EUR Mn) | 131.6 | 161.1 | 404.7 | 379.3 | 369.2 |
Non-controlling interests (EUR Mn) | 40.3 | 56.4 | 274.3 | 253.8 | 249.5 |
Total equity (EUR Mn) | 171.9 | 217.5 | 678.9 | 633.0 | 618.8 |
Net financial debt excl. leases and put options (EUR Mn) | 93.2 | 193.7 | 203.1 | 209.5 | 266.4 |
Balance Sheet (31 Dec 2024–30 Jun 2026)
| Item | 31 Dec 2024 | 30 Jun 2025 | 30 Jun 2026 |
|---|---|---|---|
Cash and equivalents (EUR Mn) | 117.3 | 90.5 | 72.0 |
Goodwill (EUR Mn) | 415.2 | 409.7 | NPD |
Other intangibles (EUR Mn) | 175.0 | 169.5 | NPD |
Gross financial debt incl. leases (EUR Mn) | 364.2 | 354.5 | NPD |
of which bank loans (EUR Mn) | 264.6 | 274.4 | NPD |
of which bonds (EUR Mn) | 27.7 | 22.2 | NPD |
of which lease liabilities (EUR Mn) | 37.4 | 34.8 | NPD |
Non-current interest-bearing debt (EUR Mn) | 267.7 | 258.7 | NPD |
Current interest-bearing debt (EUR Mn) | 59.1 | 60.9 | NPD |
Inventories incl. biological (EUR Mn) | 96.9 | 114.9 | NPD |
Trade receivables (EUR Mn) | 137.0 | 116.2 | NPD |
Trade payables (EUR Mn) | 61.6 | 74.3 | NPD |
Net financial debt (EUR Mn) | 209.5 | 229.1 | 302.7 |
Total equity (EUR Mn) | 633.0 | 606.9 | 677.8 |
Cash Flow
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net operating cash flow (EUR Mn) | 19.5 | 32.3 | 33.5 | 31.7 | 46.7 |
Cash Flow (Half-Yearly)
| Metric | H1 2024 | H1 2025 |
|---|---|---|
Operating cash flow (EUR Mn) | 21.4 | 31.4 |
Capex, tangible plus intangible (EUR Mn) | 26.6 | 27.7 |
Free cash flow, OCF minus capex (EUR Mn) | -5.2 | 3.7 |
Acquisitions net of cash (EUR Mn) | 31.1 | 7.5 |
Dividends paid to third parties/minorities (EUR Mn) | 0.4 | 2.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, group share / opening group equity (%) | 11.2 | 9.1 | 2.2 | 3.9 | 2.1 |
ROA, consolidated net / total assets (%) | 4.5 | 3.0 | 0.7 | 2.5 | 1.2 |
Solvency, equity / total assets (%) | 41.2 | 35.8 | 53.8 | 51.8 | 49.7 |
Gearing, net debt / total equity (x) | 0.54 | 0.89 | 0.30 | 0.33 | 0.43 |
Net debt / EBITDA (x) | 2.04 | 3.21 | 3.63 | 1.79 | 2.42 |
Asset turnover, revenue / total assets (x) | 0.85 | 0.85 | 0.44 | 0.57 | 0.58 |
Payout, gross dividend / group share (%) | 18.9 | 20.8 | 68.8 | 18.7 | 37.2 |
Revenue by Region
| Region | H1 2024 | H1 2025 |
|---|---|---|
Belgium revenue (EUR Mn) | 42.8 | 44.7 |
Europe ex-Belgium revenue (EUR Mn) | 107.4 | 112.0 |
Americas revenue (EUR Mn) | 152.8 | 166.5 |
Other regions revenue (EUR Mn) | 14.5 | 14.2 |
Total revenue (EUR Mn) | 317.5 | 337.4 |
Revenue by Region (%)
| Region (%) | H1 2024 share (%) | H1 2025 share (%) |
|---|---|---|
Belgium | 13.5 | 13.2 |
Europe ex-Belgium | 33.8 | 33.2 |
Americas | 48.1 | 49.4 |
Other | 4.6 | 4.2 |
Share Price & Returns
| Reference point | Price |
|---|---|
30 Jun 2024 | 68.0 (680.0 pre-split; H1 2025 report) |
30 Jun 2025 | 71.0 (710.0 pre-split) |
31 Dec 2025 | ≈66.0 (derived from −9.09% YTD to €60.00) |
30 Jun 2026 | 60.0 |
8 Oct 2026 | 60.0 |
Last close (mid-Oct 2026) | 58.5 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap (EUR Mn) | ≈583 | 9.97m shares |
P/E (FY2025 group EPS €0.811) | ≈72x | Distorted by FX, hyperinflation and purchase-price amortisation |
EV (EUR Mn) | ≈1,164 | Market cap + net debt €302.7m (Jun 2026) + book non-controlling interests €278.4m |
EV / EBITDA FY2025 | ≈10.6x | EBITDA €110.0m |
EV / EBITDA trailing (H2 2025 + H1 2026) | ≈10.2x | Trailing EBITDA ≈€114.5m |
EV / Sales FY2025 | ≈1.6x | Revenue €725.9m |
P/B (group equity €399.3m, Jun 2026) | ≈1.46x | — |
Dividend yield | ≈0.5% | €0.30 / €58.50 |
Analyst Ratings & Targets
| Broker | Rating | Target | Date |
|---|---|---|---|
KBC Securities (Guy Sips) | Accumulate | €825 pre-split (€82.5 adjusted) | Dec 2024 (Bolero) |
MarketScreener consensus | Outperform (1 analyst) | €71.00 average (+21% vs €58.50) | Oct 2026 |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross DPS split-adjusted (EUR) | 0.25 | 0.25 | 0.25 | 0.30 | 0.30 |
Bucket Details
| Bucket | Amount |
|---|---|
Bank overdrafts | 19.6 |
Due within 1 year | 46.1 |
Due in years 2–5 | 173.5 |
Due beyond 5 years | 115.3 |
Total | 354.5 |
Analyst Conclusions
Management guidance
The Board expects higher results for FY2026 (FY2025 results, 31 Mar 2026), reaffirmed as a positive outlook for the full year in the H1 2026 report. H1 2026 delivered EBITDA growth of +12.5%, with all three divisions improving. Seasonality makes H2 decisive: BIOTROP's sales peak in July–September and Food's at year-end.
Consensus
A single covering analyst (MarketScreener) rates the stock Outperform with a €71 target. Consensus revenue and EPS growth figures are NPD.
Bull case
-
BIOTROP compounding plus 100% ownership. Best-ever H1 2026, double-digit growth in FY2025 and full ownership since Oct 2026 should lift the share of BIOTROP profit flowing to BioFirst, and so to Floridienne at 59.1%.
-
Normalisation of non-operating drags. H1 2026 financial result improved to −€1.4m from −€9.8m and the hyperinflation charge fell to −€0.1m from −€0.9m. If FX stabilises, group-share EPS could rebound sharply from the FY2025 trough of €0.81.
-
Optionality on BioFirst value. The "largest pure-play biologicals group" with revenue above US$580m and EBITDA margins of about 18–20% could command a premium private or IPO valuation. That would crystallise a holding discount against a group EV/EBITDA of about 10x.
Bear case
-
Structural margin pressure at Biobest from North American competition and pest-pressure volatility. Life Sciences EBITDA fell from €102.3m to €95.4m in FY2025 and was only +€0.5m in H1 2026.
-
Leverage and liquidity. Net debt is up €100m in 2.5 years to €303m, the current ratio is 1.30x, and the BIOTROP minority buyout (provisioned but still cash) means interest cover sits at about 2.8x EBITDA and 1.1x EBIT.
-
Persistent low equity returns. Group-share ROE has been 2–4% since 2023, minority leakage is about 50%, and €9–10m of amortisation recurs. Thin liquidity and a 20% float limit any re-rating.
Catalysts and monitorables (next 12 months)
9M 2026 statement (~29 Nov 2026): BIOTROP's Q3 peak season and Biobest's North American trends.
FY2026 results (~31 Mar 2027): delivery of "higher results"; net debt trajectory; dividend.
BRL, USD and CAD versus EUR: the translation and transaction FX effects.
BIOTROP US/EU traction: first meaningful revenue disclosures for the North America platform.
SNAM volume ramp and metal prices;: Food margin sustainability through Q4.
Capital structure moves at BioFirst: any co-investor exit, refinancing or listing.
Larzul court ruling (Rennes);: goodwill impairment testing at year-end.
Analyst verdict
Floridienne has completed a decade-long metamorphosis from an eclectic Belgian conglomerate into what is, in substance, a listed, family-controlled vehicle for one of the world's most complete agricultural-biologicals platforms. The strategic logic is compelling. BioFirst now spans macrobials, microbials and pollination across protected and open-field crops, anchored by BIOTROP's leadership in Brazil, the most dynamic biologicals market globally. BIOTROP has delivered record performances every year since the December 2023 acquisition, and the October 2026 buyout of its remaining minorities removes a layer of profit leakage.
The financial translation of that strategy to Floridienne shareholders, however, remains disappointing. Consolidated EBITDA doubled between FY2023 and FY2024, yet group-share net profit in FY2025 (€7.9m) was below FY2021 (€13.2m). Four factors explain the gap: minority interests absorb half of earnings; acquisition amortisation weighs on the P&L; FX translation and Turkish hyperinflation recur; and interest costs rise as leverage climbs. At roughly 10x EV/EBITDA, the market is pricing the platform at a reasonable rather than demanding multiple. At more than 70x trailing EPS, investors are paying for a recovery that has only begun to show (H1 2026 group-share result still −€0.7m).
The H1 2026 margin recovery across all three divisions, together with management's "higher results" guidance, sets up a plausible FY2026 earnings rebound. The principal swing factors are BRL and USD rates, the North American greenhouse competitive environment, and capital discipline as net debt approaches 2.7x EBITDA.
On balance, the risk-reward appears modestly positive (Accumulate-equivalent), conditional on FY2026 delivering visibly higher group-share earnings and stable leverage. Absent that, the holding-company discount and minority leakage are likely to persist.
All figures in EUR and per IFRS unless otherwise stated; fiscal years end 31 December. "NPD" = not publicly disclosed in the sources reviewed. Derived figures are analyst calculations from company-reported data.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Notes |
|---|---|---|
Marc Blanpain | Chairman of the Board, Floridienne | Signs results releases as Chairman (FY2023 and FY2025). Tenure start, age and education NPD. |
Gaëtan Waucquez | CEO and director, Floridienne | CEO quoted since at least 2022. Holds 3.89% (38,732 pre-split shares) and is a concert party. Prior roles, education and age NPD. |
Philippe de Spoelberch | Reference shareholder (11.68% direct; linked to Beluflo per concert agreement) | Board role NPD in sources reviewed |
Jean-Marc Vandoorne | CEO, BioFirst Group | Quoted on the Oct 2026 BIOTROP buyout |
Jonas Hipólito | President, BIOTROP | Named in 2026 |
Antonio Zem | BIOTROP co-founder; sits on the BioFirst Group board | Revista Cultivar, Oct 2026 |
Andre Cerignoni | GM, BIOTROP North America (from Aug 2026) | Ex-Koppert US |
Chris Rose | BioWorks leader (with the company since 2013) | Led the 2026 leadership transition |
Major Shareholders
| Holder | Shares (pre-split) | % |
|---|---|---|
Beluflo S.A. | 400,000 | 40.13 |
Philippe de Spoelberch | 116,428 | 11.68 |
Gaëtan Waucquez | 38,732 | 3.89 |
Subtotal — shareholders' agreement signatories | 555,160 | 55.69 |
Marinvest SA | 100,000 | 10.03 |
| — | 81,524 | 8.18 |
BM Albatros | 37,500 | 3.76 |
Floridienne (treasury) | 17,363 | 1.74 |
Other / free float | 205,310 | 20.60 |
Total | 996,857 | 100.00 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type / HQ | Positioning vs. Floridienne |
|---|---|---|---|
Greenhouse biocontrol and pollination | Koppert | Private, Netherlands | Global #1/#2 in macrobials and bumblebees; main rival to Biobest, including in North America |
Greenhouse biocontrol | Bioline AgroSciences (InVivo group) | France/UK | Macrobial producer in Europe and the Americas |
Greenhouse biocontrol | Andermatt Group | Private, Switzerland | Biocontrol (viruses, macrobials), global distribution |
Biopesticides (US) | Certis Biologicals (Mitsui) | USA/Japan | US biopesticides; competes with BioWorks |
Biologicals (majors) | BASF, Syngenta Biologicals, Bayer, Corteva Biologicals (Stoller, Symborg) | Global agrochemical majors | Scale, channel power; increasingly acquisitive in biologicals |
Microbials / inoculants | Novonesis (Novozymes + Chr. Hansen) | Listed, Denmark | Microbial technology leader |
Microbials / inoculants | Lallemand Plant Care | Private, Canada | Inoculants and biostimulants |
Brazil biologicals | Koppert do Brasil, Solubio, Grupo Vittia, Simbiose, Agrivalle, UPL (NPP) | Brazil / global | Direct BIOTROP competitors; on-farm production is a further competitive threat |
Natural enzymes / extracts | Enzyme producers (e.g., Enzybel peers, Asian bromelain producers) and pancreatin makers | Various | Fragmented niche |
Food (cold sauces, specialities) | Private-label sauce makers; French gastronomy players (incl. Larzul) | Various | Fragmented, retailer-dominated |
Battery recycling | Umicore, Fortum, Hydrovolt, Accurec, Eramet/Suez initiatives | Europe | Larger-scale rivals in EV battery recycling |
PVC stabilisers | Baerlocher, Reagens, Songwon, Turkish local producers | Global / Turkey | Larger global players; Kimflor is a regional niche player |
Peer Comparison FY2025
| Metric | Floridienne (FY2025) | Koppert | Certis Biologicals |
|---|---|---|---|
Revenue | €725.9m group; €538.3m Life Sciences | — | NPD |
Revenue growth | +4.1% group; +6.1% Life Sciences | NPD | NPD |
EBITDA margin | 15.2% group; 17.7% Life Sciences | NPD | NPD |
R&D intensity | NPD | NPD | NPD |



